Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

8.895 -0.105 (-1.17%)

Streaming Delayed Price Updated: 3:00 PM EST, Mar 5, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	14,702,944
Open	9.020
Bid (Size)	8.890 (4,600)
Ask (Size)	8.900 (2,000)
Prev. Close	9.000
Today's Range	8.800 - 9.360
52wk Range	1.830 - 12.43
Shares Outstanding	391,156,513
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies ↗

Today 10:20 EST

Merck can help stabilize investors' portfolios, whereas ImmunityBio would be a source of volatility.

Via The Motley Fool

IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? ↗

Today 1:01 EST

Investors are increasingly comparing ImmunityBio and Iovance Biotherapeutics as both cancer drug developers move into catalyst-heavy phases.

Via Stocktwits

Performance

YTD	+340.3%	+340.3%
1 Month	+45.1%	+45.1%
3 Month	+304.3%	+304.3%
6 Month	+275.3%	+275.3%
1 Year	+194.5%	+194.5%

More News

IBRX Stock Drops On Investor Concerns Over Immunotherapy Launch In Saudi Arabia Amid Middle East Tensions But Analyst Sees 20% Upside ↗

March 04, 2026

Via Stocktwits

ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth

March 04, 2026

Via MarketMinute

Dow, S&P 500, Nasdaq Futures Slip As Middle East War Fuels Oil Rally: Why MU, IBRX, BATL, DJT, SE Are On Traders’ Radar Today ↗

March 03, 2026

Via Stocktwits

IBRX Stock Tumbles After-Hours: Flags ‘Terrible’ BCG Shortage As Saudi Anktiva Launch Nears Amid Middle East Tensions ↗

March 03, 2026

Via Stocktwits

IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook ↗

March 03, 2026

Via Stocktwits

IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend ↗

March 02, 2026

Via Stocktwits

ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

February 27, 2026

From ImmunityBio

Via Business Wire

IBRX Stock Ignites Retail Frenzy Ahead Of Founder’s Prime-Time TV Blitz — Traders Bets On Saudi Funding And Trump Tailwinds ↗

February 26, 2026

Via Stocktwits

IBRX Stock Rises Pre-Market After ANKTIVA Combo Shows Stronger Bladder Cancer Responses In Phase 2 Trial ↗

February 26, 2026

Via Stocktwits

ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

February 26, 2026

From ImmunityBio, Inc.

Via Business Wire

Nasdaq, S&P 500 Futures Tread Caution On Nvidia’s China Risk: Why NFLX, WBD, AAPL, CRM, AI, LRMR Are On Traders' Radar Today ↗

February 26, 2026

Via Stocktwits

ImmunityBio Founder Reaffirms Grip As Stock Plunges In Worst Selloff Since 2024 After Massive Rally ↗

February 26, 2026

Via Stocktwits

IBRX Stock Rallies Into Trump’s Big SOTU Night — Here’s What Traders Think Could Fuel The Next Move ↗

February 24, 2026

Via Stocktwits

IBRX Stock Surges Past 4-Year Highs: Analyst Sees over 50% Upside After Anktiva’s Blowout Growth ↗

February 23, 2026

Via Stocktwits

Stock Market Today, Feb. 23: ImmunityBio Surges After Anktiva Revenue Jumps 700% ↗

February 23, 2026

Via The Motley Fool

ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit

February 23, 2026

From ImmunityBio, Inc.

Via Business Wire

Check out the stocks that are attracting the most attention and driving market activity. ↗

February 23, 2026

Via Chartmill

Why ImmunityBio Stock Is Soaring Again Today ↗

February 23, 2026

Via The Motley Fool

These stocks are gapping in today's session ↗

February 23, 2026

Via Chartmill

ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 1% Pre-Market ↗

February 23, 2026

Via Stocktwits

ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally

February 23, 2026

From ImmunityBio, Inc.

Via Business Wire

Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today ↗

February 23, 2026

Via Stocktwits

IBRX Stock To Open Week On A High? Chairman Teases Anktiva’s 3-Year Expansion Plans, Hints At Cancer Breakthrough ↗

February 23, 2026

Via Stocktwits

Frequently Asked Questions

Is ImmunityBio, Inc. - Common Stock publicly traded?

Yes, ImmunityBio, Inc. - Common Stock is publicly traded.

What exchange does ImmunityBio, Inc. - Common Stock trade on?

ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for ImmunityBio, Inc. - Common Stock?

The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market

What is the current price of ImmunityBio, Inc. - Common Stock?

The current price of ImmunityBio, Inc. - Common Stock is 8.895

When was ImmunityBio, Inc. - Common Stock last traded?

The last trade of ImmunityBio, Inc. - Common Stock was at 03/05/26 03:00 PM ET

What is the market capitalization of ImmunityBio, Inc. - Common Stock?

The market capitalization of ImmunityBio, Inc. - Common Stock is 3.48B

How many shares of ImmunityBio, Inc. - Common Stock are outstanding?

ImmunityBio, Inc. - Common Stock has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.